These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38607318)

  • 1. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.
    Kabir M; Qin L; Luo K; Xiong Y; Sidi RA; Park KS; Jin J
    J Med Chem; 2024 Apr; 67(8):6880-6892. PubMed ID: 38607318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy.
    Park KS; Qin L; Kabir M; Luo K; Dale B; Zhong Y; Kim A; Wang GG; Kaniskan HÜ; Jin J
    Adv Sci (Weinh); 2023 Apr; 10(10):e2205573. PubMed ID: 36737841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
    Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
    Acta Pharmacol Sin; 2024 Aug; 45(8):1740-1751. PubMed ID: 38609561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
    Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
    Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
    Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
    Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
    Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
    Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
    Lier S; Sellmer A; Orben F; Heinzlmeir S; Krauß L; Schneeweis C; Hassan Z; Schneider C; Patricia Gloria Schäfer A; Pongratz H; Engleitner T; Öllinger R; Kuisl A; Bassermann F; Schlag C; Kong B; Dove S; Kuster B; Rad R; Reichert M; Wirth M; Saur D; Mahboobi S; Schneider G
    Bioorg Chem; 2022 Feb; 119():105505. PubMed ID: 34838332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.
    Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
    Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclimids: Degron-inspired cereblon binders for targeted protein degradation.
    Ichikawa S; Payne NC; Xu W; Chang CF; Vallavoju N; Frome S; Flaxman HA; Mazitschek R; Woo CM
    Cell Chem Biol; 2024 Jun; 31(6):1162-1175.e10. PubMed ID: 38320555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.